{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:29:09Z","timestamp":1793042949091,"version":"4.5.0"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pharmthera.2022.108192","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:25:02Z","timestamp":1650540302000},"page":"108192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future"],"prefix":"10.1016","volume":"239","author":[{"given":"Jiuliang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108192_bb0005","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40119-021-00233-7","article-title":"Aprocitentan, A dual endothelin receptor antagonist under development for the treatment of resistant hypertension","volume":"10","author":"Angeli","year":"2021","journal-title":"Cardiology and Therapy"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0030","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40262-021-01049-3","article-title":"A population pharmacokinetic model of macitentan and its active metabolite aprocitentan in healthy volunteers and patients with pulmonary arterial hypertension","volume":"60","author":"Bartolucci","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0035","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","article-title":"Endothelin: 30 years from discovery to therapy","volume":"74","author":"Barton","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0040","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/thx.54.4.372","article-title":"Effective immunosuppressive therapy in a patient with primary pulmonary hypertension","volume":"54","author":"Bellotto","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijcard.2013.12.313","article-title":"Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry","volume":"172","author":"Bergot","year":"2014","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cardfail.2009.09.008","article-title":"Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension","volume":"16","author":"Blalock","year":"2010","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0055","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/eji.201747460","article-title":"Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension","volume":"48","author":"Blum","year":"2018","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1165\/rcmb.2020-0528OC","article-title":"Improving right ventricular function by increasing BMP signaling with FK506","volume":"65","author":"Boehm","year":"2021","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0065","doi-asserted-by":"crossref","first-page":"11418","DOI":"10.1073\/pnas.0610467104","article-title":"The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted","volume":"104","author":"Bonnet","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0070","doi-asserted-by":"crossref","first-page":"L710","DOI":"10.1152\/ajplung.00311.2016","article-title":"The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension","volume":"312","author":"Breitling","year":"2017","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/537613","article-title":"Pulmonary arterial hypertension in adult-onset Still\u2019s disease: Rapid response to Anakinra","volume":"2012","author":"Campos","year":"2012","journal-title":"Case Reports in Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: A phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0085","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0090","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1093\/rheumatology\/keab118","article-title":"Factors associated with incident severe pulmonary arterial hypertension in systemic autoimmune rheumatic diseases: A nationwide study","volume":"60","author":"Chen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21542\/gcsp.2017.14","article-title":"Nitric oxide and pulmonary arterial hypertension","volume":"2017","author":"Chester","year":"2017","journal-title":"Global Cardiology Science and Practice"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0100","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0110","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors","volume":"120","author":"Clapp","year":"2015","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0120","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0125","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): Subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0130","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02472-2018","article-title":"Pulmonary arterial hypertension associated with protein kinase inhibitors: A pharmacovigilance-pharmacodynamic study","volume":"53","author":"Cornet","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1465-9921-12-128","article-title":"Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension","volume":"12","author":"Courboulin","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0140","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ekir.2019.08.001","article-title":"Sotatercept safety and effects on hemoglobin, bone, and vascular calcification","volume":"4","author":"Coyne","year":"2019","journal-title":"Kidney International Reports"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0145","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00151313","article-title":"Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension","volume":"43","author":"Cracowski","year":"2014","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0150","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/17512433.2021.1929925","article-title":"Epoprostenol for the treatment of pulmonary arterial hypertension","volume":"14","author":"Cristo Ropero","year":"2021","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0155","first-page":"1807","article-title":"Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy","volume":"19","author":"Dahl","year":"1992","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0160","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14740338.2014.859674","article-title":"Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension","volume":"13","author":"Dingemanse","year":"2014","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0170","doi-asserted-by":"crossref","first-page":"14234","DOI":"10.18632\/aging.203040","article-title":"Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension","volume":"13","author":"Dong","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0175","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.M700563200","article-title":"The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells","volume":"282","author":"Dormond","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1165\/rcmb.2013-0100OC","article-title":"Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension","volume":"49","author":"Drake","year":"2013","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pcad.2012.07.006","article-title":"Immune and inflammatory mechanisms in pulmonary arterial hypertension","volume":"55","author":"El Chami","year":"2012","journal-title":"Progress in Cardiovascular Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0190","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03957-2020","article-title":"Endothelial cells in the pathogenesis of pulmonary arterial hypertension","volume":"58","author":"Evans","year":"2021","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0200","first-page":"213","article-title":"Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model","volume":"70","author":"Fan","year":"2021","journal-title":"Physiological Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","article-title":"Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial","volume":"117","author":"Fischer","year":"2016","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11207340-000000000-00000","article-title":"Ambrisentan","volume":"11","author":"Frampton","year":"2011","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/01926230701198469","article-title":"Inhibition of ALK5 signaling induces physeal dysplasia in rats","volume":"35","author":"Frazier","year":"2007","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/13543784.2012.632408","article-title":"Imatinib mesylate for the treatment of pulmonary arterial hypertension","volume":"21","author":"ten Freyhaus","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0225","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/720305","article-title":"Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension","volume":"2010","author":"Furuya","year":"2010","journal-title":"International Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0235","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0240","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Galie","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0245","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0250","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Galie","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0255","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0260","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Galie","year":"2004","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0275","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0280","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial","volume":"371","author":"Galie","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047662","article-title":"Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells","volume":"7","author":"Gatfield","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0290","first-page":"1","article-title":"Pulmonary hypertension in 2021: Part I-definition, classification, pathophysiology, and presentation","volume":"21","author":"Gelzinis","year":"2021","journal-title":"Journal of Cardiothoracic and Vascular Anesthesia"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2018.06.003","article-title":"Inhalation of repurposed drugs to treat pulmonary hypertension","volume":"133","author":"Gessler","year":"2018","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0300","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0305","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0310","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0315","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0320","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation","volume":"181","author":"Girerd","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0325","first-page":"126","article-title":"Primary pulmonary hypertension syndrome in a female patient with systemic lupus erythematosus","volume":"64","author":"Gol\u2019dberg","year":"1986","journal-title":"Klin Med (Mosk)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0330","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/path.5170","article-title":"Bone morphogenetic protein receptor signal transduction in human disease","volume":"247","author":"Gomez-Puerto","year":"2019","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0335","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062919","article-title":"Preclinical investigation of Trifluoperazine as a novel therapeutic agent for the treatment of pulmonary arterial hypertension","volume":"22","author":"Grobs","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0345","first-page":"1055","article-title":"Primary pulmonary hypertension in a patient with systemic lupus erythematosus: Partial improvement with cyclophosphamide","volume":"20","author":"Groen","year":"1993","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0350","first-page":"406","article-title":"2020 Chinese expert-based consensus statement regarding the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension","volume":"60","author":"Group of Pulmonary, V., Interstitial Diseases Associated with Rheumatic Diseases, C. A. o. R., Immunology, P., Chinese Rheumatism Data, C., National Clinical Research Center for, D., & Immunologic, D","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0355","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14728222.2017.1275567","article-title":"Restoring BMPRII functions in pulmonary arterial hypertension: Opportunities, challenges and limitations","volume":"21","author":"Guignabert","year":"2017","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0360","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-beta receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0365","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12890-016-0237-x","article-title":"Pulmonary arterial hypertension in adult onset Still\u2019s disease: A case report of a severe complication","volume":"16","author":"Guilleminault","year":"2016","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0370","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/art.39212","article-title":"Anti-endothelin receptor type A autoantibodies in systemic lupus erythematosus-associated pulmonary arterial hypertension","volume":"67","author":"Guo","year":"2015","journal-title":"Arthritis & Rhematology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0375","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1183\/09031936.00182813","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients","volume":"44","author":"Hao","year":"2014","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0380","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","article-title":"Inflammation, growth factors, and pulmonary vascular remodeling","volume":"54","author":"Hassoun","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0385","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and Tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0390","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000492852","article-title":"Calcineurin\/NFAT signaling modulates pulmonary artery smooth muscle cell proliferation, migration and apoptosis in Monocrotaline-induced pulmonary arterial hypertension rats","volume":"49","author":"He","year":"2018","journal-title":"Cellular Physiology and Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0395","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0961203307087610","article-title":"Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: A case report","volume":"17","author":"Hennigan","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0400","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217735820","article-title":"Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension","volume":"8","author":"Hernandez-Sanchez","year":"2018","journal-title":"Pulmonary Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0405","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201906-1141OC","article-title":"Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension","volume":"201","author":"Hodgson","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0410","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0415","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17512433.2017.1322900","article-title":"Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: A pharmacology review","volume":"10","author":"Honorato Perez","year":"2017","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0420","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-018-1735-4","article-title":"Prognostic profile of systemic sclerosis: Analysis of the clinical EUSTAR cohort in China","volume":"20","author":"Hu","year":"2018","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0425","article-title":"Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0430","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/0961203314552461","article-title":"Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus? A successful case of SLE-PAH cured by methylprednisolone pulse therapy","volume":"23","author":"Huang","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0435","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0440","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0445","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0450","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0455","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"Humbert","year":"2007","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0460","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: Results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0465","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0470","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJMe2101983","article-title":"Adjuvant Nivolumab in esophageal Cancer - A new standard of care","volume":"384","author":"Ilson","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0475","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0480","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2007.09.031","article-title":"Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension","volume":"51","author":"Ivy","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0485","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/art.23303","article-title":"Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases","volume":"58","author":"Jais","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0490","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0495","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1756-185X.12324","article-title":"A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still\u2019s disease: Targeting IL-6","volume":"17","author":"Kadavath","year":"2014","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0500","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/1756-185X.12645","article-title":"Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: Results from a Korean nationwide registry","volume":"20","author":"Kang","year":"2017","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0505","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12876","article-title":"Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects","volume":"48","author":"Kato","year":"2018","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0510","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0961203311403347","article-title":"The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: Report of five cases and a literature review","volume":"20","author":"Kato","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0515","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.healun.2011.11.002","article-title":"Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study","volume":"31","author":"Kemp","year":"2012","journal-title":"The Journal of Heart and Lung Transplantation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0520","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1517\/14656560903061275","article-title":"Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension","volume":"10","author":"Kingman","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0525","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/rheumatology\/kev097","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: An observational study","volume":"54","author":"Kommireddy","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0530","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: A phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0535","doi-asserted-by":"crossref","DOI":"10.1177\/2045893218757596","article-title":"Inflammation and autoimmunity in pulmonary hypertension: Is there a role for endothelial adhesion molecules? (2017 Grover conference series)","volume":"8","author":"Kuebler","year":"2018","journal-title":"Pulmonary Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0540","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/kep398","article-title":"Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil","volume":"49","author":"Launay","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0545","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4070\/kcj.2018.0061","article-title":"Protective effect of right ventricular mitochondrial damage by cyclosporine A in Monocrotaline-induced pulmonary hypertension","volume":"48","author":"Lee","year":"2018","journal-title":"Korean Circulation Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0550","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2021.08.007","article-title":"Initial triple pharmacotherapy in pulmonary arterial hypertension: Is more necessarily better?","volume":"78","author":"Leopold","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0555","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fphar.2018.01550","article-title":"Acute Iloprost inhalation improves right ventricle function in pulmonary artery hypertension: A cardiac magnetic resonance study","volume":"9","author":"Li","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0560","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/0961203314527366","article-title":"Chinese SLE treatment and research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus","volume":"23","author":"Li","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0565","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1001-9294(10)60016-8","article-title":"Prevalence of anti-endothelial cell antibodies in patients with pulmonary arterial hypertension associated with connective tissue diseases","volume":"25","author":"Li","year":"2010","journal-title":"Chinese Medical Sciences Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0570","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bcpt.13305","article-title":"The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension","volume":"126","author":"Lindegaard Pedersen","year":"2020","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0575","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: Results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0580","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.108.821504","article-title":"Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: Potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease","volume":"119","author":"Long","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0585","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0590","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/humu.22904","article-title":"Pulmonary arterial hypertension: A current perspective on established and emerging molecular genetic defects","volume":"36","author":"Machado","year":"2015","journal-title":"Human Mutation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0595","article-title":"Mycophenolate Mofetil in a lupus patient with pulmonary hypertension","volume":"10","author":"Machireddy","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0600","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cardfail.2011.05.012","article-title":"Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure","volume":"17","author":"Martischnig","year":"2011","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0605","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0610","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0615","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0620","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: The impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0625","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0630","doi-asserted-by":"crossref","first-page":"L933","DOI":"10.1152\/ajplung.00310.2006","article-title":"Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: The rapamcyin-atorvastatin-simvastatin study","volume":"293","author":"McMurtry","year":"2007","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0635","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0640","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","article-title":"Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension","volume":"108","author":"Michelakis","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0645","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5339\/gcsp.2014.53","article-title":"Role of prostacyclin in pulmonary hypertension","volume":"2014","author":"Mitchell","year":"2014","journal-title":"Global Cardiology Science and Practice"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0650","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1253\/circj.CJ-11-0473","article-title":"Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease","volume":"75","author":"Miyamichi-Yamamoto","year":"2011","journal-title":"Circulation Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0655","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1165\/rcmb.2012-0077OC","article-title":"Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization","volume":"47","author":"Mizuno","year":"2012","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0660","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12325-009-0064-z","article-title":"Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension","volume":"26","author":"Montani","year":"2009","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0665","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0670","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0675","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.105.603001","article-title":"Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: A preliminary observational study","volume":"114","author":"Mukhopadhyay","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0680","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0685","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1177\/0961203320958055","article-title":"Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report","volume":"29","author":"Nawata","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0690","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1183\/09031936.00092311","article-title":"The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension","volume":"39","author":"Nickel","year":"2012","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0695","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/rccm.201807-1236OC","article-title":"Bone morphogenetic protein 9 is a mechanistic biomarker of Portopulmonary hypertension","volume":"199","author":"Nikolic","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0700","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lfs.2014.01.077","article-title":"Long-term patient survival with idiopathic\/heritable pulmonary arterial hypertension treated at a single center in Japan","volume":"118","author":"Ogawa","year":"2014","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0705","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0710","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0715","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0720","first-page":"657","article-title":"Rituximab treatment for pulmonary arterial hypertension in adult-onset Still\u2019s disease","volume":"31","author":"Padilla-Ibarra","year":"2013","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0725","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/13993003.01448-2015","article-title":"Role of interleukin-1 receptor 1\/MyD88 signalling in the development and progression of pulmonary hypertension","volume":"48","author":"Parpaleix","year":"2016","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0730","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-145-2-200607180-00020","article-title":"Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension","volume":"145","author":"Patterson","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0735","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.201105-0927OC","article-title":"Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension","volume":"185","author":"Perros","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0740","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12863-016-0384-3","article-title":"Mutational and clinical analysis of the ENG gene in patients with pulmonary arterial hypertension","volume":"17","author":"Pousada","year":"2016","journal-title":"BMC Genetics"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0745","first-page":"267","article-title":"<severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: A case report and review of the literature.Pdf>","volume":"32","author":"Prete","year":"2014","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0750","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1183\/09031936.00028310","article-title":"Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats","volume":"37","author":"Price","year":"2011","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0755","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0760","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00081-2018","article-title":"Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study","volume":"53","author":"Qian","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0765","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214605","article-title":"Inflammation in SLE-PAH: Good news or not?","volume":"78","author":"Qian","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0770","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/art.41740","article-title":"Predicting the risk of pulmonary arterial hypertension in systemic lupus erythematosus: A Chinese systemic lupus erythematosus treatment and research group cohort study","volume":"73","author":"Qu","year":"2021","journal-title":"Arthritis & Rhematology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0775","first-page":"1517","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: Results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0780","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/resp.12899","article-title":"Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"22","author":"Ramjug","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0785","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020971509","article-title":"Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil","volume":"10","author":"Roscigno","year":"2020","journal-title":"Pulmonary Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0790","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0795","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0800","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0805","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0810","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0815","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-10-6","article-title":"Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice","volume":"10","author":"Savale","year":"2009","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0820","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1183\/09031936.00123712","article-title":"Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension","volume":"42","author":"Savarese","year":"2013","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0825","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0830","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/eurheartj\/ehu035","article-title":"Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension","volume":"36","author":"Shah","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0835","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jcph.160","article-title":"Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"53","author":"Sherman","year":"2013","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0840","first-page":"1","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","author":"Shi","year":"2021","journal-title":"Immunopharmacology and Immunotoxicology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0845","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jmg.2008.062703","article-title":"A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension","volume":"46","author":"Shintani","year":"2009","journal-title":"Journal of Medical Genetics"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0850","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/rheumatology\/kes140","article-title":"Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: A single-Centre cohort","volume":"51","author":"Shirai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0855","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3109\/s10165-012-0828-1","article-title":"Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center","volume":"23","author":"Shirai","year":"2013","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0860","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0865","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0870","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"The European Respiratory Journal"},{"issue":"851","key":"10.1016\/j.pharmthera.2022.108192_bb0875","first-page":"e851","article-title":"A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension","volume":"151","author":"Singh","year":"2006","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0880","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0885","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0890","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: A pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0895","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0900","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0905","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0910","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0915","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0920","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","author":"Steiner","year":"2009","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0925","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous Belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis & Rhematology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0930","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2012-202865","article-title":"Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials","volume":"73","author":"Strand","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0935","first-page":"282","article-title":"Pulmonary hypertension in systemic lupus erythematosus: Evaluation of clinical characteristics and response to immunosuppressive treatment","volume":"29","author":"Tanaka","year":"2002","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0940","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-065X.2007.00519.x","article-title":"Differential release of mast cell mediators and the pathogenesis of inflammation","volume":"217","author":"Theoharides","year":"2007","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0945","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2353\/ajpath.2009.080565","volume":"174","author":"Thomas","year":"2009","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0950","doi-asserted-by":"crossref","first-page":"200ra117","DOI":"10.1126\/scitranslmed.3006674","article-title":"Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension","volume":"5","author":"Tian","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0955","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jjcc.2015.11.012","article-title":"Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension","volume":"68","author":"Tokunaga","year":"2016","journal-title":"Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163757","article-title":"Role of the immune system elements in pulmonary arterial hypertension","volume":"10","author":"Tomaszewski","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0965","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01030-2019","article-title":"Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: Results from a phase 2 randomised, parallel group, placebo-controlled trial","volume":"54","author":"Torres","year":"2019","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0970","doi-asserted-by":"crossref","first-page":"2002463","DOI":"10.1183\/13993003.02463-2020","article-title":"Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH","volume":"59","author":"Toshner","year":"2022","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0975","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/acs.jmedchem.6b00871","article-title":"Discovery of 2-((((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)a cetate (Ralinepag): An orally active prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"60","author":"Tran","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0980","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/CIRCRESAHA.118.313356","article-title":"Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension","volume":"124","author":"Tu","year":"2019","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0985","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1465-9921-9-20","article-title":"Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: A cross sectional study","volume":"9","author":"Ulrich","year":"2008","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0990","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1177\/0091270011423662","article-title":"Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"52","author":"Venitz","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb0995","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.110.978627","article-title":"Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension","volume":"123","author":"Vergadi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1000","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12890-016-0183-7","article-title":"Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: A case report","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12149-020-01461-y","article-title":"Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: A quantitative FDG-PET imaging study","volume":"34","author":"Wang","year":"2020","journal-title":"Annals of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1010","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.chest.2017.04.188","article-title":"Totally implantable IV Treprostinil therapy in pulmonary hypertension assessment of the implantation procedure","volume":"152","author":"Waxman","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2013.01.010","article-title":"Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro","volume":"701","author":"Weiss","year":"2013","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1020","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1378\/chest.09-2435","article-title":"Dramatic improvement in pulmonary hypertension with rapamycin","volume":"138","author":"Wessler","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with Oral Treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1030","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100851RR","article-title":"The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH","volume":"35","author":"Xing","year":"2021","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1035","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1253\/circj.CJ-17-0351","article-title":"Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease","volume":"82","author":"Yasuoka","year":"2018","journal-title":"Circulation Journal"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2019-0431OC","article-title":"Targeting Jak-stat signaling in experimental pulmonary hypertension","volume":"64","author":"Yerabolu","year":"2021","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200707-1083OC","article-title":"Role of the TGF-beta\/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension","volume":"177","author":"Zaiman","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: A multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/ATVBAHA.120.314639","article-title":"Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension","volume":"41","author":"Zawia","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1065","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12742","article-title":"Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation","volume":"53","author":"Zhang","year":"2020","journal-title":"Cell Proliferation"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1070","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/1756-185X.13478","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors","volume":"22","author":"Zhang","year":"2019","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.202103-0612ED","article-title":"A Phase-2 NIH-sponsored randomized clinical trial of rituximab in scleroderma-associated pulmonary arterial hypertension did not reach significance for its endpoints: End of story? Not so fast!","volume":"204","author":"Zhang","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/03009742.2015.1023829","article-title":"The effects of mycophenolate mofetil on cytokines and their receptors in pulmonary arterial hypertension in rats","volume":"44","author":"Zhang","year":"2015","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1085","first-page":"23","article-title":"PDGF mediates pulmonary arterial smooth muscle cell proliferation and migration by regulating NFATc2","author":"Zhao","year":"2021","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1090","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijcard.2017.01.097","article-title":"Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China","volume":"236","author":"Zhao","year":"2017","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2022.108192_bb1095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/labinvest.3700361","article-title":"Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension","volume":"86","author":"Zhou","year":"2006","journal-title":"Laboratory Investigation"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822000869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:23:33Z","timestamp":1759011813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822000869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":219,"alternative-id":["S0163725822000869"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108192","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108192"}}